

7. The method of claim 1, wherein the housekeeping gene is selected from the group consisting of *ALG9*, *SEPN*, *YWHAQ*, *VPS37A*, *PRRC2B*, *DOPEY2*, *NDUFB11*, *ND4*, *MRPL19*, *PSMC4*, *SF3A1*, *PUM1*, *ACTB*, *GAPD*, *GUSB*, *RPLP0*, *TFRC*, *MORF4L1*, *18S*, *PPIA*, *PGK1*, *RPL13A*, *B2M*, *YWHAZ*, *SDHA*, *HPRT1*, *TOX4* and *TPT1*.
8. The method of claim 7, wherein the housekeeping gene is *TOX4*.
9. The method any of claims 1-5, wherein the first predetermined cutoff value is at least 33% on a scale of 0-100%.
10. The method of claim 9, wherein the first predetermined cutoff value is at least 50% on a scale of 0 to 100%
11. The method of any of claims 1-6, having a sensitivity of at least 92%.
12. The method of any of claims 1-6, having a specificity of at least 95%.
13. The method any of claims 1-12, wherein at least one of the at least 38 biomarkers is RNA, cDNA, or protein.
14. The method of claim 13, wherein when the biomarker is RNA, the RNA is reverse transcribed to produce cDNA, and the produced cDNA expression level is detected.
15. The method of claim 13, wherein the expression level of the biomarker is detected by forming a complex between the biomarker and a labeled probe or primer.
16. The method of any of claims 1-15, wherein the first predetermined cutoff value is derived from a plurality of reference samples obtained from subjects not having or not diagnosed with a neoplastic disease.
17. The method of claim 16, wherein the neoplastic disease is prostate cancer.

18. The method of claim 1-15, wherein the test sample is blood, serum, plasma, or neoplastic tissue.
19. The method of claim 16, wherein each reference sample is blood, serum, plasma, or non-neoplastic tissue.
20. The method of any of claims 1-19, wherein the algorithm is XGB, RF, glmnet, cforest, CART, treebag, knn, nnet, SVM-radial, SVM-linear, NB, or mlp.
21. The method of claim 20, wherein the algorithm is XGB.
22. The method of claim 6, wherein the first time point is prior to the administration of the first therapy to the subject.
23. The method of claim 6, wherein the first time point is after the administration of the first therapy to the subject.
24. The method of claim 6, wherein the second score is significantly decreased as compared to the first score when the second score is at least 25% less than the first score.